Theravance Bioph Stock Price, News & Analysis

Theravance Biopharma (NASDAQ: TBPH) will present two rapid-fire analyses of YUPELRI (revefenacin) at the 2025 CHEST Annual Meeting in Chicago, Oct 19–22, 2025.

A retrospective claims study reported that patients adherent to YUPELRI after COPD hospital discharge had significantly fewer and less severe exacerbations and significantly lower healthcare costs versus non-adherent patients. Post-hoc analyses of a 52-week Phase 3 safety study found lower incidence of moderate-to-severe exacerbations and overall less severe exacerbations versus tiotropium. Presentation details list presenters, titles, and Oct 21, 2025 times.

Theravance Biopharma (NASDAQ: TBPH) will present two rapid-fire analyses of YUPELRI (revefenacin) at the 2025 CHEST Annual Meeting in Chicago, Oct 19–22, 2025.

A retrospective claims study reported that patients adherent to YUPELRI after COPD hospital discharge had significantly fewer and less severe exacerbations and significantly lower healthcare costs versus non-adherent patients. Post-hoc analyses of a 52-week Phase 3 safety study found lower incidence of moderate-to-severe exacerbations and overall less severe exacerbations versus tiotropium. Presentation details list presenters, titles, and Oct 21, 2025 times.

Theravance Biopharma (NASDAQ: TBPH) announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference in New York City. CEO Rick Winningham will engage in a Fireside Chat on September 9, 2025, at 1:30 PM EDT.

The company will offer in-person meeting opportunities for interested investors through H.C. Wainwright representatives. A live webcast will be available online, with a replay accessible on Theravance's website for 30 days following the event.

Theravance Biopharma (NASDAQ: TBPH) has completed enrollment in its pivotal Phase 3 CYPRESS study of ampreloxetine for treating symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). The study targets an underserved population of approximately 40,000 U.S. patients.

The CYPRESS trial is a global, randomized-withdrawal study with a 12-week open-label portion followed by an 8-week randomized phase. The company expects topline results in Q1 2026 and plans to pursue an expedited NDA submission with potential priority FDA review. Ampreloxetine has received Orphan Drug Designation in the U.S., highlighting the significant unmet need in treating nOH due to MSA.

Theravance Biopharma (NASDAQ:TBPH) reported strong Q2 2025 financial results, highlighted by YUPELRI® net sales of $66.3 million, representing a 22% year-over-year increase. The company completed a significant transaction, selling its TRELEGY ELLIPTA royalty interest to GSK for $225 million.

Key financial metrics include total revenue of $26.2 million and a net income of $54.8 million. The company maintains a robust balance sheet with $338.8 million in cash and no debt. The pivotal Phase 3 CYPRESS study for ampreloxetine is expected to complete enrollment by late summer, with top-line data anticipated six months later.

TRELEGY's year-to-date performance puts it on track to trigger a $50 million milestone payment in 2025, with Q2 2025 global net sales reaching approximately $1.1 billion.

Theravance Biopharma (NASDAQ: TBPH) has scheduled its second quarter 2025 financial results announcement and business update for August 12, 2025, after market close. The company will host a conference call and webcast at 5:00 pm ET on the same day.

Interested participants can pre-register for the telephone conference, while those preferring to listen via the internet can access the webcast through the company's website. A replay will be available for 30 days through September 11, 2025.

Theravance Biopharma (NASDAQ: TBPH) announced its participation in the upcoming BTIG Virtual Biotechnology Conference. The company will engage in a fireside chat on Wednesday, July 30 at 12:00 pm ET (9:00 am PT/5:00 pm IST). Senior management will also be available for one-on-one meetings with investors during the conference.

Interested parties can access the webcast or schedule meetings through their BTIG representative or by emailing uscorporateaccess@btig.com.

Theravance Biopharma (NASDAQ:TBPH) announced that its partner Viatris has received approval from China's NMPA for YUPELRI® (revefenacin), the first once-daily nebulized LAMA for COPD maintenance treatment in China.

The approval triggers a $7.5 million milestone payment to TBPH, with potential for additional sales-based milestones up to $37.5 million and tiered royalties of 14% to 20% on net sales in China. Viatris will handle all commercialization aspects.

TBPH's financial position includes $131 million in cash, $225 million from TRELEGY royalties sale to GSK, 35% of U.S. YUPELRI profits, and up to $150 million in potential TRELEGY milestone payments.

Theravance Biopharma (TBPH) has agreed to sell its remaining royalty interest in Trelegy Ellipta to GSK for $225 million in cash. This deal follows the company's 2022 transaction with Royalty Pharma that generated $1.1 billion upfront. TBPH retains rights to potential milestone payments of up to $150 million from Royalty Pharma based on Trelegy's sales performance in 2025 ($50M for ~$3.41B in sales) and 2026 ($100M for ~$3.51B in sales). The transaction represents the first outcome from the Strategic Review Committee's efforts to maximize shareholder value, with the Board remaining committed to returning excess capital to shareholders. The total potential lifetime value from Trelegy Ellipta monetization efforts could reach $1.525 billion, including previous transactions.